Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AMT-151 by Multitude therapeutics for Malignant Pleural Mesothelioma: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData,...
AMT-151 by Multitude therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
AMT-151 by Multitude therapeutics for Fallopian Tube Cancer: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
AMT-151 by Multitude therapeutics for Endometrial Cancer: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
AMT-151 by Multitude therapeutics for Peritoneal Cancer: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...
AMT-151 by Multitude therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
AMT-151 by Multitude therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
AMT-151 by Multitude therapeutics for Lung Adenocarcinoma: Likelihood of Approval
AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase...